Inside AstraZeneca’s abandoned UK vaccine plant deal as Labour and Tories face questions over £450m collapse - AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl M ...
Q4 2024 Management View CEO Pascal Soriot highlighted a strong 2024 performance with total revenue up 21% and core EPS growth at 19%, reflecting solid business momentum supported by pipeline ...
The positive recommendation from NICE for osimertinib was based on results from the ADAURA Phase III trial. In which, adjuvant treatment (after surgery) with osimertinib in patients with stage II ...
AstraZeneca says it plans to participate in the next round of Medicare negotiations under the Inflation Reduction Act. But this time around, the company says … ...
Credit: Roland Magnusson via Getty Images. AstraZeneca has received two separate recommendations from England’s National Institute for Health and Care Excellence (NICE) for the use of its lung cancer ...
FDA approves AstraZeneca's Datroway, reducing breast cancer progression risk by 37% per TROPION-Breast01 trial results. Datroway's safety profile remains consistent, with 4.2% ILD rate ...
Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...
DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca. DATROWAY is the ...
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), in patients with a certain type of breast cancer. The drug, developed ...
A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...
AstraZeneca and Daiichi Sankyo won U.S. approval for a novel breast cancer treatment, a milestone in the companies’ efforts to turn the medicine into a widely used blockbuster. The Food and Drug ...
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the U.S. regulatory finish line. The FDA has greenlighted the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback